Literature DB >> 23205068

Multimodality therapy for metastatic sarcomas confined to the lung.

Russell P Gollard1, J Francis Turner.   

Abstract

Metastectomy or resection of sarcomas which have metastasized to the lung from other sites has a long and established history. At present, there are more than forty different drugs with activity in soft tissue sarcomas. A number of sarcomas demonstrate differential sensitivities to chemotherapy and targeted agents. Intimate knowledge of the biological behavior of each distinct type of sarcoma should predicate what treatment or protocol is most suitable. Certain patients might benefit from either neoadjuvant or adjuvant therapy following the resection of metastatic lesions. Much remains to be learned about the differential sensitivities of various sarcomas to different treatment regimens.

Entities:  

Year:  2012        PMID: 23205068      PMCID: PMC3506706          DOI: 10.3892/ol.2012.820

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  67 in total

Review 1.  Update on the management of connective tissue malignancies.

Authors:  Michael Fanucchi
Journal:  Semin Oncol       Date:  2004-04       Impact factor: 4.929

2.  Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.

Authors:  S Frustaci; F Gherlinzoni; A De Paoli; M Bonetti; A Azzarelli; A Comandone; P Olmi; A Buonadonna; G Pignatti; E Barbieri; G Apice; H Zmerly; D Serraino; P Picci
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

3.  Activity of Sorafenib against desmoid tumor/deep fibromatosis.

Authors:  Mrinal M Gounder; Robert A Lefkowitz; Mary Louise Keohan; David R D'Adamo; Meera Hameed; Cristina R Antonescu; Samuel Singer; Katherine Stout; Linda Ahn; Robert G Maki
Journal:  Clin Cancer Res       Date:  2011-03-29       Impact factor: 12.531

4.  A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas.

Authors:  Xavier Garcia del Muro; Antonio Lopez-Pousa; Javier Martin; Jose M Buesa; Javier Martinez-Trufero; Antonio Casado; Andres Poveda; Josefina Cruz; Isabel Bover; Joan Maurel
Journal:  Cancer       Date:  2005-10-15       Impact factor: 6.860

5.  Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study.

Authors:  M Zalupski; B Metch; S Balcerzak; W S Fletcher; R Chapman; J D Bonnet; G R Weiss; J Ryan; R S Benjamin; L H Baker
Journal:  J Natl Cancer Inst       Date:  1991-07-03       Impact factor: 13.506

Review 6.  Surgical treatment of metastatic pulmonary soft-tissue sarcoma.

Authors:  C Chao; M Goldberg
Journal:  Oncology (Williston Park)       Date:  2000-06       Impact factor: 2.990

7.  Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

Authors:  Robert G Maki; David R D'Adamo; Mary L Keohan; Michael Saulle; Scott M Schuetze; Samir D Undevia; Michael B Livingston; Matthew M Cooney; Martee L Hensley; Monica M Mita; Chris H Takimoto; Andrew S Kraft; Anthony D Elias; Bruce Brockstein; Nathalie E Blachère; Mark A Edgar; Lawrence H Schwartz; Li-Xuan Qin; Cristina R Antonescu; Gary K Schwartz
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

8.  A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies.

Authors:  Christine M Hartford; Apurva A Desai; Linda Janisch; Theodore Karrison; Victor M Rivera; Lori Berk; John W Loewy; Hedy Kindler; Walter M Stadler; Heather L Knowles; Camille Bedrosian; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

Review 9.  Surgical therapy of lung metastases.

Authors:  David I Sternberg; Joshua R Sonett
Journal:  Semin Oncol       Date:  2007-06       Impact factor: 4.929

10.  Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases.

Authors:  A H Aljubran; A Griffin; M Pintilie; M Blackstein
Journal:  Ann Oncol       Date:  2009-01-19       Impact factor: 32.976

View more
  1 in total

1.  Aberrant Wnt/β-catenin signaling and elevated expression of stem cell proteins are associated with osteosarcoma side population cells of high tumorigenicity.

Authors:  Xi-Jun Yi; Yu-Hua Zhao; Li-Xiang Qiao; Chun-Lei Jin; Jing Tian; Qiu-Shi Li
Journal:  Mol Med Rep       Date:  2015-07-02       Impact factor: 2.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.